Vir Biotechnology (VIR) Operating Margin (2018 - 2026)
Vir Biotechnology recorded quarterly Operating Margin of 456172.41% in Q1 2026, down 609798.93% quarter-over-quarter from 74.79% in Q4 2025, and down 45156994.0% year-over-year from N/an in Q1 2025.
Vir Biotechnology's Operating Margin history runs 9 years deep, the most recent figure standing at 456172.41% for Q1 2026.
- In Q1 2026, Operating Margin fell 45156994.0% year-over-year to 456172.41%; the TTM figure through Mar 2026 stood at 720.14% (up 237958.0% YoY), while the FY2025 annual figure was 699.18%, up 9210.0% from the prior year.
- Operating Margin came in at 456172.41% for Q1 2026 at Vir Biotechnology, down from 74.79% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 82.26% in Q1 2022 to a low of 456172.41% in Q1 2026.
- A 5-year average of 33727.91% and a median of 946.74% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin soared 811025 bps in 2022 and plunged 45156994 bps in 2026, its largest moves.
- Vir Biotechnology's Operating Margin stood at 304.6% in 2022, then sank by 172 bps to 828.12% in 2023, then slipped by 14 bps to 946.74% in 2024, then surged by 92 bps to 74.79% in 2025, then plunged by 609799 bps to 456172.41% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 456172.41%, 74.79%, and 72267.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -456,172.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -456,172.41% |
| Dec 31, 2025 | -74.79% |
| Sep 30, 2025 | -72,267.92% |
| Jun 30, 2025 | -9,754.28% |
| Mar 31, 2025 | -4,602.47% |
| Dec 31, 2024 | -946.74% |
| Sep 30, 2024 | -9,718.66% |
| Jun 30, 2024 | -5,158.70% |
| Mar 31, 2024 | -154.90% |
| Dec 31, 2023 | -828.12% |
| Sep 30, 2023 | -7,075.86% |
| Jun 30, 2023 | -5,667.26% |
| Mar 31, 2023 | -227.73% |
| Dec 31, 2022 | -304.60% |
| Sep 30, 2022 | 52.05% |
| Jun 30, 2022 | -554.34% |
| Mar 31, 2022 | 82.26% |
| Dec 31, 2021 | 70.35% |
| Sep 30, 2021 | -51.52% |
| Jun 30, 2021 | 36.25% |
| Mar 31, 2021 | -8,027.99% |
| Dec 31, 2020 | -6,251.67% |
| Sep 30, 2020 | -4,544.35% |
| Jun 30, 2020 | -67.09% |
| Mar 31, 2020 | -1,257.61% |
| Dec 31, 2019 | -6,506.02% |
| Sep 30, 2019 | -3,398.43% |
| Jun 30, 2019 | -1,747.39% |
| Mar 31, 2019 | -840.48% |
| Dec 31, 2018 | -857.20% |
| Sep 30, 2018 | -1,190.50% |